Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody engineering and modification technologies.

David Filpula1

  • 1Enzon Pharmaceuticals, Piscataway, NJ 08854-3969, USA. david.filpula@enzon.com

Biomolecular Engineering
|May 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.

Molecular cancer therapeutics·2008
Same author

Releasable PEGylation of proteins with customized linkers.

Advanced drug delivery reviews·2007
Same author

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Bioconjugate chemistry·2007
Same author

Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.

Bioconjugate chemistry·2006
Same author

A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.

Protein engineering, design & selection : PEDS·2006
Same author

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

Bioconjugate chemistry·2006

Antibody engineering advances drug discovery, focusing on producing fully human monoclonal antibodies and improving protein stability. Current research explores targeted antibody therapeutics, integrating bioconjugate chemistry and protein engineering for novel treatments.

Area of Science:

  • Biotechnology
  • Immunology
  • Drug Development

Background:

  • Antibody engineering has yielded clinically approved therapeutics, with a focus on fully human monoclonal antibodies.
  • Antibodies, as large macromolecules, present significant challenges in formulation, pharmacokinetics, manufacturing, and stability.
  • Advancements in discovery technologies enable rapid screening and refinement of binding molecules.

Purpose of the Study:

  • To review the current state and future directions of antibody engineering.
  • To highlight the challenges and progress in antibody production, stability, and targeted drug development.
  • To discuss the convergence of bioconjugate chemistry and protein engineering in antibody therapeutics.

Main Methods:

  • Review of antibody discovery technologies (e.g., phage display, ribosome display, transgenic animals).

Related Experiment Videos

  • Analysis of strategies for improving protein production, stability, and effector functions.
  • Exploration of minimal binding proteins and non-immunoglobulin scaffolds for targeted drug delivery.

    • Main Results:

    • Significant progress in producing fully human monoclonal antibodies for clinical use.
    • Ongoing efforts to enhance antibody production, stability, and effector domain properties.
    • Increasing exploration of targeted antibody therapeutics, including antibody-drug conjugates.

    Conclusions:

    • Antibody engineering is a mature field with ongoing innovation in antibody production and function.
    • The development of targeted antibody drugs is a key area of current research, integrating multiple disciplines.
    • Future antibody therapeutics will likely involve complex bioconjugates and engineered protein scaffolds.